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In kidney transplant recipients, cardiovascular disease (CVD) is the leading cause of death. The
relationship of kidney function with CVD outcomes in transplant recipients remains uncertain. We
performed a post-hoc analysis of the Folic Acid for Vascular Outcome Reduction in
Transplantation (FAVORIT) Trial to assess risk factors for CVD and mortality in kidney
transplant recipients. Following adjustment for demographic, clinical and transplant
characteristics, and traditional CVD risk factors, proportional hazards models were used to explore
the association of estimated GFR with incident CVD and all-cause mortality. In 4016 participants,
mean age was 52 years and 20% had prior CVD. Mean eGFR was 49±18 mL/min/1.73m2. In
3,676 participants with complete data, there were 527 CVD events over a median of 3.8 years.
Following adjustment, each 5 mL/min/1.73m2 higher eGFR at levels below 45 mL/min/1.73m2
was associated with a 15% lower risk of both CVD [HR = 0.85 (0.80, 0.90)] and death [HR = 0.85
(0.79, 0.90)], while there was no association between eGFR and outcomes at levels above 45 mL/
min/1.73m2. In conclusion, in stable kidney transplant recipients, lower eGFR is independently
associated with adverse events, suggesting that reduced kidney function itself rather than pre-
existing comorbidity may lead to CVD.
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INTRODUCTION
In kidney transplant recipients, cardiovascular disease (CVD) is the leading cause of
mortality, accounting for 30% of deaths among recipients who die with a functioning
transplant (1). Reduced kidney function, typically quantified as estimated glomerular
filtration rate (eGFR), is an independent risk factor for CVD in the general population, in
part, reflecting the close association of CVD risk factors and glomerular filtration rate
(GFR). The relationship of GFR to CVD risk in transplant recipients may differ following
transplantation, because the level of GFR may no longer reflect lifelong exposure to CVD
risk factors (2). Accordingly, better understanding of the epidemiology and risk factors for
CVD in this population is critically important to identify higher risk transplant recipients and
potentially treat modifiable risk factors.
Several retrospective studies have assessed CVD outcomes in kidney transplant recipients.
To date, the association between GFR and subsequent CVD remains uncertain, with most
existing data drawn from administrative registries and clinical databases, suggesting an
association between kidney function and CVD events in transplant recipients (3–4).
Recently, the PORT Study, a retrospective registry of 23,575 incident kidney transplant
recipients from 14 transplant centers, demonstrated that traditional CVD risk factors, non-
traditional CVD risk factors, and transplant-specific factors predicted future CVD events in
this population (3), while, in a subset of the PORT registry, lower estimated GFR (eGFR) 1-
year post-transplant was associated with increased mortality (5). Similarly, a retrospective
single center study in Belgium evaluated over 2,000 kidney transplant recipients who
survived at least 1 year following transplantation and noted that traditional CVD risk factors
and transplant-specific risk factors were associated with future CVD events (6). Large
prospective studies with rigorous ascertainment of CVD events systematically evaluating the
association between kidney function and CVD outcomes in transplant recipients are limited
to a post hoc analysis of 1052 participants in the Assessment of Lescol in Renal
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Transplantation (ALERT) Study that described age, diabetes, electrocardiogram changes and
worse allograft function as factors associated with fatal CVD (7–8).
Accordingly, we analyzed data from the Folic Acid for Vascular Outcome Reduction in
Transplantation (FAVORIT) Trial cohort, a randomized study examining the effect of B-
vitamin therapy on CVD and mortality outcomes in 4110 prevalent, stable kidney transplant
recipients (9), in order to explore risk factors for CVD and all-cause mortality in kidney
transplant recipients, specifically focusing on the relationship between eGFR and outcomes.
METHODS
Study Design
The current report is a post hoc analysis of FAVORIT (clinicaltrials.gov: NCT00064753), a
multi-center double-blind randomized controlled clinical trial conducted to determine
whether lowering homocysteine levels with vitamin therapy reduced the rate of pooled
arteriosclerotic CVD outcomes. FAVORIT was approved by the Institutional Review
Boards at the participating institutions (see acknowledgements), and methods are described
in detail elsewhere (9–10). FAVORIT randomized 4110 stable kidney transplant recipients
from August 2002 through January 2007 to either a standard multivitamin with high doses
of folic acid (5 mg), vitamin B6 (pyridoxine; 50 mg) and vitamin B12 (cyanocobalamin; 1
mg) versus a multivitamin containing low doses of vitamin B6 (1.4 mg) and vitamin B12 (2
µg) with no folic acid. Follow-up contacts occurred every six months through January 31,
2010 to obtain study related outcomes through June 24, 2009. As there were no differences
between randomized groups in study outcomes, we combined both groups for these
analyses.
Study population
Men and women age 35 to 75 years who were at least 6 months post-kidney transplant were
screened for eligibility at 30 transplant centers in the United States, Canada and Brazil.
Recruitment in Brazil began later in the study than recruitment at United States and
Canadian sites. Entry criteria included stable kidney function, initially defined by an
estimated creatinine clearance ≥ 30 mL/min in both men and women and redefined after
July 7, 2005 in women only as ≥ 25 mL/min, and elevated serum homocysteine level (≥ 11
µmol/L for women; ≥ 12 µmol/L for men).
Serum Creatinine and eGFR
Analyses used serum creatinine data drawn at the baseline study visit and assayed from
frozen sera available in 4016 (98.0%) participants following a single thaw. Serum creatinine
was measured in 2011 at the FAVORIT central laboratory at the United States Department
of Agriculture Jean Mayer Human Nutrition Research Center on Aging at Tufts University
using an alkaline picrate kinetic method on an Olympus AU 400e (Olympus America Inc,
Center Valley, PA) instrument that is calibrated to an isotope dilution mass spectrometry
traceable standard. GFR was estimated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation, a newer estimating equation with better performance at
higher GFR levels (11–12). An eGFR of 60–74 ml/min per 1.73 m2 was selected as the
reference group for categorical analyses, since this range is the highest level of measured
GFR expected for a single kidney, and higher eGFR values may reflect decreased creatinine
generation, which may be associated with increased mortality (13–15).
Other Baseline Variables
Baseline characteristics at study enrollment included demographics (age, sex, race, country
of origin); smoking status (current, former or never); past medical history (baseline CVD,
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diabetes mellitus); transplant characteristics (living donor kidney, time since transplant);
physical examination findings (body mass index (BMI), systolic and diastolic blood
pressure); and laboratory variables (serum creatinine, homocysteine, total cholesterol, high
density lipoprotein (HDL) cholesterol, and triglycerides). Baseline blood pressure was the
average of two measurements and hypertension was defined by systolic blood pressure ≥140
mm Hg, diastolic ≥90 mm Hg or antihypertensive medication use at study enrollment.
Diabetes was defined by the use of insulin or oral hypoglycemic medications or patient
history. Baseline CVD was defined as prior myocardial infarction, coronary artery
revascularization, stroke, carotid arterial revascularization, abdominal or thoracic aortic
aneurysm repair, and/or lower extremity arterial revascularization. Race was defined as
white, black, or other, with individuals who identified as ‘other’ classified as white for
eGFR estimation. The 27 individuals missing data on race were defined as white for GFR
estimation. Body mass index was calculated using the formula: weight [kg]/ height [m]2.
Low-density lipoprotein (LDL) cholesterol was estimated using the Friedewald equation at
triglyceride levels below 400 and measured in the 234 participants with triglyceride levels
above 400 mg/dL (16).
Study Outcomes
The primary CVD outcome is a composite of CVD death, myocardial infarction,
resuscitated sudden death, stroke, coronary revascularization, or peripheral, carotid, aortic or
renal artery procedures. The first four components of this primary outcome were centrally
reviewed and adjudicated by the FAVORIT Clinical Endpoints Committee; the remaining
outcomes were identified through medical record abstraction. The Clinical Endpoints
Committee also reviewed records for unstable angina cases and urgent coronary
revascularization procedures in search of myocardial infarctions that were not identified by
the clinical site staff. The secondary outcome is all-cause mortality. To account for semi-
competing risks, we also examined a composite outcome of CVD and all-cause mortality.
For primary analyses, participants were not censored at the time of return to dialysis or at re-
transplantation.
Statistical Analyses
Linear regression for continuous variables and chi-square tests for categorical variables were
used to compare baseline data by eGFR group. Kaplan-Meier survival analysis was used to
estimate the survival function among study participants by eGFR level. Cox proportional-
hazards regression was used to examine the association between baseline covariates and
time to study outcomes. Parsimonious models were a priori adjusted for age, sex, race,
diabetes, prior CVD, treatment allocation and country of origin, while, reflecting the
available data in FAVORIT, extended multivariable models were a priori further adjusted
for smoking, systolic blood pressure, BMI, LDL cholesterol, HDL cholesterol, triglyceride
level, transplant vintage, and living versus deceased donor kidney. Non-violation of the
proportional hazards assumption was assessed through visual examination of the log-log plot
of survival. Several potentially clinically important interaction terms with kidney function
were tested, including with prior CVD and with transplant vintage. Two sensitivity analyses
were performed. The first examined the relationship of eGFR and other covariates with the
composite CVD outcome and the all-cause mortality outcomes, censoring 3-months after
return to dialysis. The second included total homocysteine in extended models. All analyses
were performed using SAS 9.2. Dr. Carpenter had full access to all the data in the study and
takes responsibility for the integrity of the data and the accuracy of the data analysis.
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Among 4110 enrolled participants, 94 were excluded for missing baseline creatinine, leaving
4,016 participants described in Table 1. Mean age was 52 (SD, 9) years; 37% were women,
40% diabetic and 20% had a history of CVD. Mean eGFR was 48.9 (SD, 17.7) mL/min/
1.73m2 and median time since kidney transplant was 4.0 (25th–75th percentile, 1.7–7.4)
years. Individuals with lower eGFR were older, had longer duration since transplant and
higher systolic blood pressure, were more often white and women, and were more likely to
have a history of CVD. HDL cholesterol was significantly lower and triglycerides
significantly higher in participants with lower eGFR (Table 1).
The final population with complete data for CVD analyses included 3,676 (91.5%)
participants; of the initial 4,016 participants with eGFR results, 27 were excluded for
missing race, 46 for loss to follow-up, 46 for missing baseline clinical data (history of CVD
or smoking), 135 for missing cholesterol data, 57 for missing blood pressure or BMI, and 27
for missing data on transplant characteristics (Figure 1). Participants excluded for missing
data were similar to included participants with the exception of significantly fewer
participants from Brazil being excluded (data not shown). Adjusted mortality analyses
included 3,714 participants as an additional 36 participants had data on vital status at study
completion. Administrative censoring occurred on June 24, 2009, at which time 2,788
participants remained enrolled in the trial, 493 participants were deceased, 822 had
incomplete follow-up, and 7 participants had no follow-up.
There were 584 CVD events and 493 deaths, with 37 CVD events and 62 deaths occurring
more than 3 months after dialysis-dependent recurrent kidney failure. Among the 3,676
participants with complete data, there were 527 CVD events over mean follow-up time of
3.8 (SD 1.6) years (comprising the primary composite endpoint), with a higher proportion of
events occurring at lower eGFR levels. When eGFR was examined as a categorical variable
in clinically relevant groups, risk increased only with progressively lower eGFR levels
below 45 mL/min per 1.73m2 (Table 2, Figure 2a). Accordingly, in parsimonious Cox
proportional hazards models adjusting for age, sex, race, treatment assignment, country,
baseline CVD and diabetes, each 5 mL/min per 1.73m2 higher eGFR for eGFR levels below
45 mL/min per 1.73m2 was associated with a 17% lower risk of a CVD event [Hazard Ratio
(HR) = 0.83 (0.78, 0.88), p<0.0001] while there was no relationship appreciated for eGFR
levels above 45 [HR = 1.01 (0.97, 1.05), p=0.74]; this effect was unchanged in extended
multivariable models [HR = 0.85 (0.80, 0.90), p<0.0001 for each 5 mL/min per 1.73m2 rise
at eGFR below 45 mL/min per 1.73m2 and HR = 1.01 (0.96, 1.05), p=0.74 for each 5 mL/
min per 1.73m2 rise at eGFR above 45 mL/min per 1.73m2]. Other factors significantly
associated with greater CVD risk in transplant recipients included several traditional CVD
risk factors, such as older age, prior CVD, diabetes, current smoking, and higher systolic
blood pressure. Other traditional CVD risk factors, including sex, LDL cholesterol and
triglycerides were non-significant, while HDL cholesterol was of borderline statistical
significance and lower BMI and lower diastolic blood pressure were associated with
increased CVD risk. The impact of eGFR on CVD outcomes was comparable to that of
systolic blood and age. Interactions for eGFR with prior CVD and with transplant vintage
were non-significant (p=0.37 and 0.83, respectively). The breakdown of events comprising
the CVD outcome is shown in Table 3 along with event-specific risk by baseline eGFR.
Among 3,712 participants with complete data for vital status, there were 439 deaths over
mean follow-up time of 4.0 (SD 1.5) years, with a higher proportion of events occurring at
lower eGFR levels (Figure 1). When eGFR was examined as a categorical variable, the
lowest risk group had eGFR between 60 and 74 mL/min per 1.73 m2, although this was
relationship was nearly identical to that associated with an eGFR of 45–59 or above 75 mL/
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min per 1.73 m2 (Table 2, Figure 2b). Factors associated with all-cause mortality were
similar to those associated with a CVD event (Table 2). In parsimonious Cox proportional
hazards models adjusting for age, sex, race, treatment assignment, country, baseline CVD
and diabetes, each 5 mL/min per 1.73m2 higher eGFR below 45 mL/min per 1.73m2 was
associated with a 16% lower risk of death [Hazard Ratio (HR) = 0.84 (0.79, 0.89),
p<0.0001] while there was no relationship appreciated for eGFR levels above 45 [HR = 0.99
(0.95, 1.03), p=0.61]; this effect was unchanged in extended multivariable models [HR =
0.85 (0.79, 0.90), p<0.0001 for each 5 mL/min per 1.73m2 rise at eGFR below 45 mL/min
per 1.73m2 and HR = 1.00 (0.95, 1.04), p=0.86 for each 5 mL/min per 1.73m2 rise at eGFR
above 45 mL/min per 1.73m2]. Interactions for eGFR with prior CVD and with transplant
vintage were non-significant (p=0.53 and 0.41, respectively). Analyses examining a
composite outcome of CVD and all-cause mortality were similar (Table 2).
Sensitivity analyses revealed similar results. In extended multivariable models censoring 3-
months after recurrent kidney failure, each 5 mL/min per 1.73 m2 higher eGFR up to an
eGFR of 45 mL/min per 1.73m2 was associated with 14% lower CVD event risk [HR = 0.86
(0.81, 0.92), p<0.0001] and 12% lower mortality risk [HR = 0.88 (0.82, 0.95), p=0.0006],
with no significant relationship at eGFR levels above 45 mL/min per 1.73m2. Models
evaluating censored outcomes stratified by clinically relevant eGFR group also remained
similar (Figure 3). Homocysteine level was not significant in CVD models, but higher
homocysteine level was associated with all-cause mortality [HR = 1.02 (1.01, 1.04,
p<0.0001) for each µmol/L increase]; inclusion of homocysteine level in models did not
substantially impact the relationship between eGFR and outcomes (data not shown).
DISCUSSION
In stable kidney transplant recipients, lower eGFR is strongly and independently associated
with both CVD events and all-cause mortality, specifically at levels below 45 mL/min per
1.73m2. Similar to the general population and the PORT registry, those transplant recipients
with the highest eGFR values (≥75 mL/min per 1.73m2) did not have a lower risk of death
than individuals with much lower eGFR results. These findings expand considerably on two
recent studies (3, 7) by exploring the relationship between eGFR, including CKD stage, and
outcomes in a large, generalizable transplant cohort with rigorous ascertainment of CVD
events and calibrated serum creatinine values. Critically, the current study identifies
transplant patients with lower eGFR as being at increased risk of major outcomes in addition
to progression to kidney failure, suggesting that transplant recipients, particularly those with
lower eGFR, may be a high-yield population for research into strategies for CVD risk
reduction.
The presence of an association between low eGFR and cardiovascular disease in transplant
recipients suggests that comorbid conditions associated with low GFR itself rather than
concurrent comorbidities that result in both low GFR as well as systemic cardiovascular
disease may be impacting cardiovascular risk. In the general population, reduced eGFR is
independently associated with CVD events and mortality (17–20). It is likely that this
relationship reflects several processes, including a greater duration and severity of
traditional CV risk factors in individuals with reduced GFR, the effects of non-traditional
CV risk factors that accompany reduced GFR (21–22), and perhaps effects of reduced GFR
itself. Finding a similar relationship in kidney transplant recipients as in the general
population suggests a possible direct effect of reduced GFR, since the transplanted kidney is
likely to not have had a long exposure to traditional and non-traditional CVD risk factors.
These findings are particularly important as many kidney transplant recipients receive less
aggressive CVD risk factor management than would be expected given their underlying
comorbid burden (23).
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In 2002, the National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative
(KDOQI) proposed a CKD classification system, which stratified chronic kidney disease
into stages based on eGFR levels (24). This has been widely adopted, with CKD stage 3 to
be subdivided into stage 3a (eGFR 45–59 mL/min per 1.73 m2) and stage 3b (eGFR 30–44
mL/min per 1.73 m2) for better risk assessment (25). To date, this classification system is
not adequately studied in transplant recipients (26–27). The current study adds to the
literature on the utility of the CKD classification system, which now divides stage 3 into two
categories, by showing progressively increased risk of both CVD and mortality outcomes in
univariate and multivariable adjusted analyses at eGFR levels below 45 mL/min per 1.73 m2
and a flat risk relationship at eGFR levels above 45 mL/min per 1.73 m2; this considerably
expands on the findings in the ALERT Study, where risk was quantified based on each 1
mg/dL increment of serum creatinine (7, 28). This relationship in FAVORIT is supported by
findings for all-cause mortality from the PORT registry study (5), but conflicts with a single-
center study of 431 transplant recipients where there was no significant relationship between
CKD stage and mortality (29). Importantly, this latter study did not subdivide CKD stage 3
to appreciate the gradated risk that is seen within this stage and had few patients with CKD
stage 2 or CKD stage 4 (29).
The current study has multiple strengths. These are most notable for the large size of the
FAVORIT cohort as well as the extensive ascertainment of CVD risk factors, the systematic
prospective ascertainment of CVD events, and the measurement of serum creatinine at a
single laboratory. Additionally, kidney transplant recipients are among the healthiest of
kidney failure patients, with most having undergone pre-transplant CVD screening, although
the value of this screening remains uncertain (30–31). There are also several weaknesses.
First, we lack data on albuminuria; however, albuminuria may be a less important risk factor
in transplant recipients than in individuals in the general population, reflecting that 1) in
some transplant recipients albuminuria may be from the native kidneys rather than the
transplant, and 2) in individuals without a kidney transplant, albuminuria likely is a kidney
marker of lifelong vascular burden (18, 32–35). Whether the level of albuminuria in a
transplant kidney reflects current systemic vascular disease burden requires further study.
Second, eGFR was estimated based on a single assessment of serum creatinine; however, we
were able to confirm the results presented in this manuscript by performing similar analyses
using creatinine values assayed at the time of screening for FAVORIT eligibility.
Additionally, despite the potential inaccuracies with a single ascertainment, which would
bias to a null finding, the relationship between eGFR and CVD and mortality outcomes
remained highly significant in the FAVORIT cohort. Third, we are relying on data from a
randomized clinical trial analyzed as a cohort. However, the clinical trial was negative,
finding no effect of the vitamin intervention on outcomes (36). Additionally, we adjust for
intervention assignment in all analyses.
In conclusion, in a large, generalizable prevalent kidney transplant population, we have
identified a substantial and graded association between eGFR and subsequent CVD and
mortality outcomes. Further research is essential to evaluate strategies to modify this risk.
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Flowchart of FAVORIT cohort members. Censored analyses indicate individuals for whom
event ascertainment ceased at 3 months post-dialysis initiation.
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Adjusted survival estimates for (A) Primary CVD outcomes and (B) All-cause mortality
outcomes stratified by baseline eGFR. Figures depict the product-limit estimates of the
survivor function at mean levels for continuous covariates and for the reference group as
displayed in Table 2 for categorical variables. Analyses exclude participants with missing
covariate data.
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Hazard of CVD and mortality outcomes in extended models censoring 3-months after
recurrent kidney failure.
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